deltatrials
Completed PHASE3 NCT00614120

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2
Interventions glimepiride liraglutide metformin placebo
Updated 8 times since 2017 Last updated: Jan 25, 2017 Started: Jan 31, 2008 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

Listed as NCT00614120, this PHASE3 trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — May 2017 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India, Bangalore, India, Beijing, China, Bhubaneswar, India, Chennai, India, Chongqing, China, Fuzhou, China, Ghaziabad, India, Goyang, South Korea, Hangzhou, China and 27 more location s